Saturday, March 23, 2019 2:42:50 PM
Crown Bridge Partners, LLC
is a New York-based privately held investment firm that prides itself in offering sensible, responsive and non-disruptive direct institutional investment to small to mid - cap publicly traded companies
We work diligently with the management of the companies we align ourselves with in order to better understand the unique challenges they face and the opportunities they can take advantage of when well-capitalized. Crown Bridge looks to build long term relationships with the companies it funds and as such, our business model and rule (not the exception) provides the opportunity for additional tranches of funding on a continual basis.
Unlike a hedge fund, we are a family office that does not raise any capital from outside 3rd party investors. Therefore, we are never subject to any outside pressure nor are we ever met with any redemption requests.
We are in the business of directly investing our capital in the issuers and management teams that we believe in. That focus gives us the flexibility to adapt our terms to reflect each issuer’s needs and the agility to move quickly from introduction to funding.
We look to utilize a number of different instruments to infuse capital into a broad range of publicly traded securities including direct equity, convertible securities, warrants, derivatives and structured products: as long as the terms make sense for both sides we will give any structure serious consideration.
Recent NEWH News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:30:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:30:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 10:00:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:30:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 08:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 08:56:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 08:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 08:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2023 08:30:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM